包涵體肌炎市場規模、佔有率和成長分析：按治療方法、診斷方法、最終用戶、分銷管道和地區分類－2026-2033年產業預測

2024 年全球包涵體肌炎市場價值為 5.425 億美元，預計到 2033 年將從 2025 年的 5.7017 億美元成長至 8.488 億美元，在預測期（2026-2033 年）內複合年成長率為 5.1%。

全球包涵體肌炎市場的主要驅動力是診斷能力的提升和臨床意識的增強，這導致患者群體不斷擴大，治療研究投入也隨之增加。這種進行性性發炎性肌肉疾病多發於50歲以上的成年人，會導致肌肉無力和身體殘疾。該市場涵蓋診斷、藥物治療和支持性護理服務。標準化自體抗體抗體組合和MRI方案的最新進展，完善了流行病學研究，並促進了標靶臨床試驗的發展。監管獎勵和策略聯盟正在推動藥物研發，而孤兒藥資格認定則加速了臨床試驗進程，並優先考慮與包涵體肌炎相關的項目。此外，人工智慧正在革新診斷和藥物研發，改進影像檢測、生物標記提取和試驗設計，最終推動更有效率的研究、更精準的患者群體，並在這一不斷變化的領域中拓展治療選擇。

全球口腔肌炎市場成長要素

全球包涵體肌炎市場主要受益於治療研究的進展，這些進展加深了我們對該疾病潛在機制的理解。這些進展促成了新分子標靶和創新治療策略的發現，並在建造研發管線中發揮至關重要的作用。臨床前模型的改進和候選化合物篩選的最佳化吸引了研究人員的專業投資，鼓勵製藥和生物技術公司投入資源進行深入的研究舉措。與學術機構的合作進一步加速了潛在治療方法的成熟，提高了開發平臺的成功率，最終推動市場成長並增強了相關人員的信心。

全球口腔肌炎市場的限制因素

由於人們對現有治療方法的有效性持續存在擔憂，全球包涵體肌炎市場面臨嚴峻挑戰。醫療專業人員、保險公司和投資者的猶豫不決阻礙了創新治療方法的推廣應用，並降低了人們對全面研發舉措的熱情。臨床結果不明確或病患療效僅有輕微改善，使得臨床實驗招募困難、法規核准流程受阻，並阻礙了醫保報銷談判。這些因素共同導致相關人員在後期研發和市場准入計畫的投資上猶豫不決，從而延誤了新治療方法惠及病患的進程。

頰肌炎的全球市場趨勢

受診斷技術進步的推動，全球上束肌炎市場正經歷顯著成長。先進的影像學和分子檢測技術正在改變診斷格局，使患者能夠更早、更準確地與其他肌肉疾病區分開來。這項發展有助於做出更精準的臨床決策，更有效地識別患者，最終擴大了適合標靶治療的患者群體。此外，數位病理工作流程的整合以及學術研究機構與當地醫療機構之間合作的加強，為治療方法的發展和循證醫學證據的積累構建了更強大的框架。這些進步不僅降低了診斷的不確定性，也改善了這種棘手疾病的整體治療狀況。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球包涵體肌炎市場規模：依治療類型分類

• 藥物治療
  • 皮質類固醇
  • 免疫抑制劑
• 物理治療及職能治療
• 臨床實驗藥物和臨床試驗藥物
• 其他

全球包涵體肌炎市場規模：依診斷方法分類

• 肌肉切片檢查
• 肌電圖（圖）
• 磁振造影
• 其他

全球包涵體肌炎市場規模：依最終用戶分類

• 神經科專科診所
• 醫院及復健中心
• 學術研究機構
• 其他

全球包涵體肌炎市場規模：依分銷管道分類

• 醫院藥房
• 零售藥房
• 僅限線上銷售的藥房
• 其他

全球包涵體肌炎市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Novartis
• Biogen
• Sanofi
• Abcuro
• Orphazyme
• Milo Biotechnology
• Kezar Life Sciences
• Orbus Therapeutics
• Regeneron Pharmaceuticals
• Bristol Myers Squibb
• Pfizer
• Teva Pharmaceutical
• Takeda Pharmaceutical
• Immunovant
• argenx
• Amgen
• CSL Behring
• Octapharma
• Grifols
• Kedrion Biopharma

結論與建議

Global Inclusion Body Myositis Market size was valued at USD 542.5 Million in 2024 and is poised to grow from USD 570.17 Million in 2025 to USD 848.8 Million by 2033, growing at a CAGR of 5.1% during the forecast period (2026-2033).

The global inclusion body myositis market is primarily driven by enhanced diagnostic capabilities and heightened clinical awareness, leading to an increased patient population and greater investment in therapeutic research. This progressive inflammatory myopathy affects adults over 50, resulting in muscle weakness and disability. The market encompasses diagnostics, pharmacological treatments, and supportive care services. Recent advancements in standardized autoantibody panels and MRI protocols have refined epidemiology and facilitated targeted clinical trials. With regulatory incentives and strategic collaborations boosting development, orphan drug designations are expediting trial processes and prioritizing inclusion body myositis programs. Additionally, AI is revolutionizing diagnosis and drug development, improving image detection, biomarker extraction, and trial design, ultimately fostering more efficient research, enhanced patient stratification, and increased treatment options in this evolving landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Inclusion Body Myositis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Inclusion Body Myositis Market Segments Analysis

Global inclusion body myositis market is segmented by treatment type, diagnosis method, end-user, distribution channel and region. Based on treatment type, the market is segmented into Pharmacological Therapy, Physical and Occupational Therapy, Investigational and Clinical Trial Drugs and Others. Based on diagnosis method, the market is segmented into Muscle Biopsy, Electromyography, Magnetic Resonance Imaging and Others. Based on end-user, the market is segmented into Specialized Neurology Clinics, Hospitals and Rehabilitation Centers, Academic and Research Institutes and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Specialty Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Inclusion Body Myositis Market

The Global Inclusion Body Myositis market is significantly driven by advancements in therapeutic research that have enhanced our understanding of the disease's underlying mechanisms. This progress has led to the discovery of new molecular targets and innovative treatment strategies, which play a crucial role in shaping development pipelines. By improving preclinical models and refining candidate selection, researchers are attracting specialized investment, encouraging pharmaceutical and biotech companies to dedicate resources to focused research initiatives. Collaborations with academic institutions further expedite the maturation of potential treatments, elevating the chances of success in clinical development and ultimately fostering market growth and boosting stakeholder confidence.

Restraints in the Global Inclusion Body Myositis Market

The Global Inclusion Body Myositis market faces significant challenges due to ongoing concerns about the effectiveness of available treatments. This hesitance among healthcare providers, insurers, and investors hampers the adoption of innovative therapies and diminishes the motivation for comprehensive development initiatives. When clinical results are ambiguous or only offer minimal improvement in patient outcomes, it complicates the recruitment of participants for trials, intensifies the scrutiny during regulatory processes, and raises difficulties in reimbursement discussions. These factors collectively discourage stakeholders from investing in late-stage development and planning for market access, ultimately delaying the introduction of new treatments for those affected.

Market Trends of the Global Inclusion Body Myositis Market

The Global Inclusion Body Myositis market is witnessing significant growth driven by advancements in diagnostic technologies. Enhanced imaging modalities and molecular assays are transforming the diagnostic landscape, facilitating earlier and more precise differentiation from other myopathies. This evolution supports more accurate clinical decision-making and effective patient identification, ultimately expanding the patient population eligible for targeted therapies. Furthermore, the integration of digital pathology workflows and the promotion of collaborative efforts between academic research centers and community healthcare providers are fostering a more robust framework for treatment development and evidence generation. Such progress not only reduces diagnostic uncertainty but also enhances the overall treatment landscape for this challenging condition.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Inclusion Body Myositis Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Pharmacological Therapy
  • Corticosteroids
  • Immunosuppressants
• Physical and Occupational Therapy
• Investigational and Clinical Trial Drugs
• Others

Global Inclusion Body Myositis Market Size by Diagnosis Method & CAGR (2026-2033)

• Market Overview
• Muscle Biopsy
• Electromyography
• Magnetic Resonance Imaging
• Others

Global Inclusion Body Myositis Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Specialized Neurology Clinics
• Hospitals and Rehabilitation Centers
• Academic and Research Institutes
• Others

Global Inclusion Body Myositis Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Specialty Pharmacies
• Others

Global Inclusion Body Myositis Market Size & CAGR (2026-2033)

• North America (Treatment Type, Diagnosis Method, End-User, Distribution Channel)
  • US
  • Canada
• Europe (Treatment Type, Diagnosis Method, End-User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Diagnosis Method, End-User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Diagnosis Method, End-User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Diagnosis Method, End-User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abcuro
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orphazyme
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Milo Biotechnology
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kezar Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orbus Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunovant
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• argenx
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion Biopharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations